Anthropic and the Gates Foundation are teaming up on a $200 million AI push for global health; Quartz, May 14, 2026

  

Cris Tolomia , Quartz; Anthropic and the Gates Foundation are teaming up on a $200 million AI push for global health

"Anthropic and the Gates Foundation are committing $200 million over four years to deploy AI across global health, education, and economic mobility programs, the organizations said on Thursday.

Under the terms of the arrangement, the Gates Foundation will bring grant funding, program design, and expertise, while Anthropic's contribution takes the form of Claude AI usage credits and support from its technical staff, Reuters reported. Anthropic said the partnership is central to its efforts to extend AI's benefits in areas where markets alone will not.

The largest portion of the funding will focus on improving health outcomes in low- and middle-income countries, where about 4.6 billion people lack access to essential health services, Anthropic said. Specific initiatives include using Claude to screen potential drug and vaccine candidates for neglected diseases such as polio, HPV, and eclampsia, as well as working with the Gates Foundation's Institute for Disease Modeling to improve forecasts for where treatments for diseases such as malaria and tuberculosis are deployed."

Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries; The New York Times, October 2, 2024

 Stephanie Nolen , The New York Times; Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries

"The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North Africa to make and sell at a lower price its groundbreaking drug lenacapavir, a twice-yearly injection that provides near-total protection from infection with H.I.V.

Those companies will be permitted to sell the drug in 120 countries, including all the countries with the highest rates of H.I.V., which are in sub-Saharan Africa. Gilead will not charge the generic drugmakers for the licenses.

Gilead says the deal, made just weeks after clinical trial results showed how well the drug works, will provide rapid and broad access to a medication that has the potential to end the decades-long H.I.V. pandemic.

But the deal leaves out most middle- and high-income countries — including Brazil, Colombia, Mexico, China and Russia — that together account for about 20 percent of new H.I.V. infections. Gilead will sell its version of the drug in those countries at higher prices. The omission reflects a widening gulf in health care access that is increasingly isolating the people in the middle."